Klotho Neurosciences (KLTO) Competitors $0.26 +0.01 (+2.62%) As of 03/27/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsOwnershipSEC FilingsTrendsBuy This Stock KLTO vs. SNYR, ELEV, PULM, TNXP, MRNS, IRD, VRCA, UBX, AKTX, and GDTCShould you be buying Klotho Neurosciences stock or one of its competitors? The main competitors of Klotho Neurosciences include Synergy CHC Corp. (Uplisting) (SNYR), Elevation Oncology (ELEV), Pulmatrix (PULM), Tonix Pharmaceuticals (TNXP), Marinus Pharmaceuticals (MRNS), Opus Genetics (IRD), Verrica Pharmaceuticals (VRCA), Unity Biotechnology (UBX), Akari Therapeutics (AKTX), and CytoMed Therapeutics (GDTC). These companies are all part of the "pharmaceutical products" industry. Klotho Neurosciences vs. Synergy CHC Corp. (Uplisting) Elevation Oncology Pulmatrix Tonix Pharmaceuticals Marinus Pharmaceuticals Opus Genetics Verrica Pharmaceuticals Unity Biotechnology Akari Therapeutics CytoMed Therapeutics Klotho Neurosciences (NASDAQ:KLTO) and Synergy CHC Corp. (Uplisting) (NASDAQ:SNYR) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, valuation, community ranking, media sentiment, analyst recommendations, institutional ownership and risk. Do insiders and institutionals have more ownership in KLTO or SNYR? 20.1% of Klotho Neurosciences shares are held by institutional investors. 2.0% of Klotho Neurosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has better valuation & earnings, KLTO or SNYR? Klotho Neurosciences has higher earnings, but lower revenue than Synergy CHC Corp. (Uplisting). CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKlotho NeurosciencesN/AN/A$1.35MN/AN/ASynergy CHC Corp. (Uplisting)$26.01M1.07N/AN/AN/A Does the MarketBeat Community believe in KLTO or SNYR? Synergy CHC Corp. (Uplisting) received 2 more outperform votes than Klotho Neurosciences when rated by MarketBeat users. CompanyUnderperformOutperformKlotho NeurosciencesN/AN/ASynergy CHC Corp. (Uplisting)Outperform Votes266.67% Underperform Votes133.33% Is KLTO or SNYR more profitable? Company Net Margins Return on Equity Return on Assets Klotho NeurosciencesN/A N/A -25.89% Synergy CHC Corp. (Uplisting) N/A N/A N/A Do analysts recommend KLTO or SNYR? Synergy CHC Corp. (Uplisting) has a consensus price target of $10.00, indicating a potential upside of 211.53%. Given Synergy CHC Corp. (Uplisting)'s stronger consensus rating and higher possible upside, analysts plainly believe Synergy CHC Corp. (Uplisting) is more favorable than Klotho Neurosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Klotho Neurosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Synergy CHC Corp. (Uplisting) 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Does the media refer more to KLTO or SNYR? In the previous week, Klotho Neurosciences and Klotho Neurosciences both had 2 articles in the media. Klotho Neurosciences' average media sentiment score of 0.94 equaled Synergy CHC Corp. (Uplisting)'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Klotho Neurosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Synergy CHC Corp. (Uplisting) 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummarySynergy CHC Corp. (Uplisting) beats Klotho Neurosciences on 7 of the 9 factors compared between the two stocks. Remove Ads Get Klotho Neurosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for KLTO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KLTO vs. The Competition Export to ExcelMetricKlotho NeurosciencesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.10M$3.04B$5.64B$8.06BDividend YieldN/A1.54%4.56%4.02%P/E RatioN/A29.2923.1319.03Price / SalesN/A436.17383.8993.17Price / Cash0.95168.6838.1634.64Price / Book-0.123.956.944.33Net Income$1.35M-$71.95M$3.20B$247.06M7 Day Performance-4.73%-4.62%-2.32%-0.53%1 Month Performance-24.50%-9.29%3.07%-3.74%1 Year PerformanceN/A-25.74%11.16%1.72% Klotho Neurosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KLTOKlotho NeurosciencesN/A$0.26+2.6%N/AN/A$7.10MN/A0.00N/ASNYRSynergy CHC Corp. (Uplisting)3.6495 of 5 stars$3.58+0.8%$10.00+179.3%N/A$31.16M$26.01M0.0040Gap DownELEVElevation Oncology2.4512 of 5 stars$0.53-1.3%$6.83+1,199.4%-94.8%$31.14MN/A-0.6440PULMPulmatrix0.2164 of 5 stars$8.39-0.8%N/A+341.8%$30.62M$10.01M-3.1820Earnings ReportPositive NewsTNXPTonix Pharmaceuticals2.4772 of 5 stars$16.28+8.5%$1,100.00+6,656.8%-97.5%$30.43M$11.29M0.0050Short Interest ↑MRNSMarinus Pharmaceuticals2.3609 of 5 stars$0.55-0.2%$4.79+771.6%-93.8%$30.32M$30.99M-0.22110Analyst ForecastNews CoverageIRDOpus Genetics2.357 of 5 stars$0.94+0.7%$8.00+749.6%N/A$29.72M$8.38M-0.8614VRCAVerrica Pharmaceuticals4.2703 of 5 stars$0.65+21.1%$9.50+1,360.4%-92.3%$29.66M$7.57M-0.3640UBXUnity Biotechnology4.1495 of 5 stars$1.75-1.1%$7.33+319.0%-27.6%$29.52M$240,000.00-1.3460Analyst ForecastAnalyst RevisionAKTXAkari TherapeuticsN/A$1.10+1.9%N/A-27.8%$29.25MN/A0.009Analyst ForecastGap DownGDTCCytoMed Therapeutics2.4923 of 5 stars$2.65+6.9%$5.00+88.7%+0.7%$28.99MN/A0.00N/AShort Interest ↓Positive News Remove Ads Related Companies and Tools Related Companies Synergy CHC Corp. (Uplisting) Competitors Elevation Oncology Competitors Pulmatrix Competitors Tonix Pharmaceuticals Competitors Marinus Pharmaceuticals Competitors Opus Genetics Competitors Verrica Pharmaceuticals Competitors Unity Biotechnology Competitors Akari Therapeutics Competitors CytoMed Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KLTO) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersA $6.9 Trillion Cash Tsunami Is Coming – Move Your Money NOWExpert: "Prepare For the Mother of All Melt-Ups" In the wake of Wall Street volatility, stock-picking legen...Stansberry Research | SponsoredElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Klotho Neurosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Klotho Neurosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy KLTO Stock Free KLTO Stock Alerts